Cutting Edge Technology to Improve Ancient Medicines

Apollon Formularies appoints long-time advisor and shareholder as non-exec director

Apollon Formularies appoints long-time advisor and shareholder as non-exec director

The new appointment has "a demonstrable record of growing small cap companies and creating shareholder value of many business ventures over a long career," said CEO Stephen Barnhill

Apollon Formularies PLC (AQSE:APOL) appointed Rod McIllree, a 29.06% shareholder, as a non-executive director with immediate effect and said it expects to appoint "further high-profile directors" to the board in the coming months.

McIllree, who currently owns 217,485,940 ordinary shares in the company, was "instrumental" in bringing Apollon to the AQSE Growth Market last April, the company said.

He has advised, funded and run public companies for more than 20 years across multiple global exchanges in several sectors, the company said, with specific experience in technology, mining, international logistics and finance.

Apollon said in a statement that McIllree has been a long-time advisor to the company and his appointment "strengthens the board at a time that the company expects to experience significant growth".

Chief executive Stephen Barnhill said McIllree has "a demonstrable record of growing small cap companies and creating shareholder value of many business ventures over a long career".

"He brings a wealth of financial and directorial experience to the team, and I look forward to working with him as we move our business towards the global rollout of Apollon's product range and medical expertise to supportive jurisdictions."

McIllree said: "Apollon is an excellent example of utilising research and development to help improve people's lives. The compelling results of Apollon's formulations killing cancer cells in 3D-cell culture and the upcoming opening of the International Cancer and Chronic Pain Institute in Jamaica are important milestones for the company and offers outstanding potential on many fronts.

"I look forward to working with Dr Barnhill and the wider Apollon team at this exciting time for growth as the company looks to execute on the various business partnership opportunities becoming available."

< Back to News